405 related articles for article (PubMed ID: 30553446)
1. Difference in IgA1 O-glycosylation between IgA deposition donors and IgA nephropathy recipients.
Nakazawa S; Imamura R; Kawamura M; Kato T; Abe T; Namba T; Iwatani H; Yamanaka K; Uemura M; Kishikawa H; Nishimura K; Oka K; Tajiri M; Wada Y; Nonomura N
Biochem Biophys Res Commun; 2019 Jan; 508(4):1106-1112. PubMed ID: 30553446
[TBL] [Abstract][Full Text] [Related]
2. Elucidating heterogeneity of IgA1 hinge-region O-glycosylation by use of MALDI-TOF/TOF mass spectrometry: role of cysteine alkylation during sample processing.
Franc V; Řehulka P; Raus M; Stulík J; Novak J; Renfrow MB; Šebela M
J Proteomics; 2013 Oct; 92():299-312. PubMed ID: 23891555
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of IgA1 O-glycosylation in Henoch-Schönlein Purpura Nephritis Using Mass Spectrometry.
Nakazawa S; Imamura R; Kawamura M; Kato T; Abe T; Iwatani H; Yamanaka K; Uemura M; Kishikawa H; Nishimura K; Tajiri M; Wada Y; Nonomura N
Transplant Proc; 2019 Jun; 51(5):1481-1487. PubMed ID: 31084922
[TBL] [Abstract][Full Text] [Related]
4. Post-transplant immunoglobulin A deposition and nephropathy in allografts.
Sofue T; Suzuki H; Ueda N; Kushida Y; Minamino T
Nephrology (Carlton); 2018 Jul; 23 Suppl 2():4-9. PubMed ID: 29968406
[TBL] [Abstract][Full Text] [Related]
5. Mass spectrometry proves under-O-glycosylation of glomerular IgA1 in IgA nephropathy.
Hiki Y; Odani H; Takahashi M; Yasuda Y; Nishimoto A; Iwase H; Shinzato T; Kobayashi Y; Maeda K
Kidney Int; 2001 Mar; 59(3):1077-85. PubMed ID: 11231363
[TBL] [Abstract][Full Text] [Related]
6.
Dotz V; Visconti A; Lomax-Browne HJ; Clerc F; Hipgrave Ederveen AL; Medjeral-Thomas NR; Cook HT; Pickering MC; Wuhrer M; Falchi M
J Am Soc Nephrol; 2021 Oct; 32(10):2455-2465. PubMed ID: 34127537
[TBL] [Abstract][Full Text] [Related]
7. Recognition of galactose-deficient O-glycans in the hinge region of IgA1 by N-acetylgalactosamine-specific snail lectins: a comparative binding study.
Gomes MM; Suzuki H; Brooks MT; Tomana M; Moldoveanu Z; Mestecky J; Julian BA; Novak J; Herr AB
Biochemistry; 2010 Jul; 49(27):5671-82. PubMed ID: 20507092
[TBL] [Abstract][Full Text] [Related]
8. Identification of distinct glycoforms of IgA1 in plasma from patients with immunoglobulin A (IgA) nephropathy and healthy individuals.
Lehoux S; Mi R; Aryal RP; Wang Y; Schjoldager KT; Clausen H; van Die I; Han Y; Chapman AB; Cummings RD; Ju T
Mol Cell Proteomics; 2014 Nov; 13(11):3097-113. PubMed ID: 25071157
[TBL] [Abstract][Full Text] [Related]
9. Aberrantly glycosylated serum IgA1 are closely associated with pathologic phenotypes of IgA nephropathy.
Xu LX; Zhao MH
Kidney Int; 2005 Jul; 68(1):167-72. PubMed ID: 15954905
[TBL] [Abstract][Full Text] [Related]
10. Enzymatic sialylation of IgA1 O-glycans: implications for studies of IgA nephropathy.
Takahashi K; Raska M; Stuchlova Horynova M; Hall SD; Poulsen K; Kilian M; Hiki Y; Yuzawa Y; Moldoveanu Z; Julian BA; Renfrow MB; Novak J
PLoS One; 2014; 9(2):e99026. PubMed ID: 24918438
[TBL] [Abstract][Full Text] [Related]
11. Mass spectrometry analysis of IgA1 hinge region in patients with IgA nephropathy.
Gastaldi D; Paradisi L; Baiocchi C; Medana C; Lo Duca G; Sena LM; Roccatello D
J Nephrol; 2007; 20(6):689-95. PubMed ID: 18046671
[TBL] [Abstract][Full Text] [Related]
12. Immune characteristics of renal allograft donors with mesangial IgA deposition.
Wang Z; Zhang X; Han W; Yu G; Ying Z; Xu X; Wang M; Zhou X; Lv J; Zhang H
Int Immunopharmacol; 2021 Feb; 91():107282. PubMed ID: 33370682
[TBL] [Abstract][Full Text] [Related]
13. Quantitative change of IgA hinge O-glycan composition is a novel marker of therapeutic responses of IgA nephropathy.
Iwatani H; Inoue T; Wada Y; Nagasawa Y; Yamamoto R; Iijima H; Takehara T; Imai E; Rakugi H; Isaka Y
Biochem Biophys Res Commun; 2012 Nov; 428(3):339-42. PubMed ID: 23098908
[TBL] [Abstract][Full Text] [Related]
14. Serum under-O-glycosylated IgA1 level is not correlated with glomerular IgA deposition based upon heterogeneity in the composition of immune complexes in IgA nephropathy.
Satake K; Shimizu Y; Sasaki Y; Yanagawa H; Suzuki H; Suzuki Y; Horikoshi S; Honda S; Shibuya K; Shibuya A; Tomino Y
BMC Nephrol; 2014 Jun; 15():89. PubMed ID: 24928472
[TBL] [Abstract][Full Text] [Related]
15. IgA nephropathy: characterization of IgG antibodies specific for galactose-deficient IgA1.
Suzuki H; Moldoveanu Z; Hall S; Brown R; Julian BA; Wyatt RJ; Tomana M; Tomino Y; Novak J; Mestecky J
Contrib Nephrol; 2007; 157():129-33. PubMed ID: 17495450
[TBL] [Abstract][Full Text] [Related]
16. The glycans deficiencies of macromolecular IgA1 is a contributory factor of variable pathological phenotypes of IgA nephropathy.
Xu LX; Yan Y; Zhang JJ; Zhang Y; Zhao MH
Clin Exp Immunol; 2005 Dec; 142(3):569-75. PubMed ID: 16297170
[TBL] [Abstract][Full Text] [Related]
17. O-glycoforms of polymeric immunoglobulin A1 in the plasma of patients with IgA nephropathy are associated with pathological phenotypes.
Yu G; Zhang Y; Meng B; Xie X; Wang Z; Ying W; Lv J; Zhang H
Nephrol Dial Transplant; 2021 Dec; 37(1):33-41. PubMed ID: 34152412
[TBL] [Abstract][Full Text] [Related]
18. Analyses of IgA1 hinge glycopeptides in IgA nephropathy by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry.
Hiki Y; Tanaka A; Kokubo T; Iwase H; Nishikido J; Hotta K; Kobayashi Y
J Am Soc Nephrol; 1998 Apr; 9(4):577-82. PubMed ID: 9555659
[TBL] [Abstract][Full Text] [Related]
19. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies.
Tomana M; Novak J; Julian BA; Matousovic K; Konecny K; Mestecky J
J Clin Invest; 1999 Jul; 104(1):73-81. PubMed ID: 10393701
[TBL] [Abstract][Full Text] [Related]
20. Analysis of IgA1 O-glycans in IgA nephropathy by fluorophore-assisted carbohydrate electrophoresis.
Allen AC; Bailey EM; Barratt J; Buck KS; Feehally J
J Am Soc Nephrol; 1999 Aug; 10(8):1763-71. PubMed ID: 10446944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
